Ascendis Pharma A/S
Denmark · DK0060615755 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Good
- Revenue +98% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Good
- It earned 140% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?To watch
- Equity is -12% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€720M
revenue
-19%
operating margin
−€228M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €51M | €267M | €364M | €720M |
| Operating profit | −€562M | −€456M | −€279M | −€136M |
| Net profit to shareholders | −€583M | −€481M | −€378M | −€228M |
| Earnings per share | −€0.10 | −€0.09 | −€0.07 | −€0.04 |
| Cash from operations | −€496M | −€467M | −€306M | €54M |
| Capital spending | €14M | €2M | n/a | n/a |
| Cash | €445M | €392M | €560M | €616M |
| Total assets | €1.1B | €826M | €1.2B | €1.3B |
| Equity | €263M | −€146M | −€106M | −€163M |
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.